BrainQ

Executive Summary

BrainQ is an Israeli med-tech company pioneering an AI-driven, low-intensity electromagnetic stimulation device for home-based stroke rehabilitation. The system leverages machine learning to analyze individual neural activity and deliver personalized stimulation patterns, aiming to accelerate functional recovery and reduce long-term disability. Founded in 2018, BrainQ has raised $40M to advance its technology through Phase 2 clinical trials. The device addresses a critical unmet need in stroke care, where current rehabilitation is often clinic-based, costly, and limited in accessibility. By enabling home-based therapy, BrainQ has the potential to improve patient outcomes and reduce healthcare burdens. The company's technology is non-invasive and designed for ease of use, positioning it as a scalable solution for the millions of stroke survivors worldwide. Positive trial results could pave the way for regulatory submissions and commercialization, making BrainQ a promising player in the neurology med-tech space. BrainQ's upcoming milestones are centered on clinical validation and regulatory advancement. The company is expected to complete its pivotal Phase 2 trial, with data readout anticipated in the next two quarters. Additionally, securing FDA Breakthrough Device Designation could expedite the regulatory pathway and attract strategic partnerships. These catalysts, combined with strong preclinical and early clinical data, support a compelling risk-reward profile. The management team's execution and the device's differentiated approach will be key to realizing its potential in the stroke rehabilitation market.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Trial Data Readout60% success
• Q3 2026FDA Breakthrough Device Designation70% success
• Q1 2027Strategic Partnership for Commercialization50% success